Litwin Andre S, Patel Bhupendra, McNab Alan A, McCann John D, Leatherbarrow Brian, Malhotra Raman
Corneoplastic Unit, Queen Victoria Hospital NHS Trust, East Grinstead, West Sussex, UK.
Division of Facial and Orbital Cosmetic & Reconstructive Surgery, Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
Br J Ophthalmol. 2015 Jul;99(7):899-902. doi: 10.1136/bjophthalmol-2014-306335. Epub 2015 Jan 16.
BACKGROUND/AIMS: To review our approach of cautious surgical correction of blepharoptosis in patients with myasthenia gravis (MG) to minimise risk of exposure complications.
Retrospective case note review of 30 patients with symptomatic eyelid concerns despite appropriate medical treatment, who underwent eyelid surgery. The mean age at diagnosis was 47 years. 13/30 patients had systemic MG, 14/30 ocular MG and 3/30 congenital MG. The main outcome measures were improvement in eyelid height and/or position, duration of a successful postoperative result, need for further surgical intervention, and intraoperative or postoperative complications.
38 blepharoptosis procedures were performed on 23 patients. Mean age at time of surgery was 62 years, with an average follow-up of 29 months. 10 patients (16 eyelids) underwent anterior approach levator advancement, 4 patients (5 eyelids) posterior approach surgery and 8 patients (15 eyelids) brow suspension. One patient (2 eyelids) had tarsal switch surgery. An average improvement in eyelid height of 1.9 mm was achieved. Postoperative symptoms or signs of exposure keratopathy occurred in 17% of patients. This necessitated lid lowering in one eyelid of one patient. During follow-up, 37% of eyelids required further surgical intervention to improve the upper eyelid height, after an average of 19 months (range 0.5-49 months).
Over a third of patients in our series required repeat surgery, which would be expected when the initial aim was to under-correct this group. In contrast to previous commentaries, the amount of eyelid excursion was not the main factor used to guide the surgical approach.
背景/目的:回顾我们对重症肌无力(MG)患者进行上睑下垂谨慎手术矫正的方法,以将暴露性并发症的风险降至最低。
对30例经适当药物治疗后仍有症状性眼睑问题并接受眼睑手术的患者进行回顾性病例记录审查。诊断时的平均年龄为47岁。30例患者中13例患有全身性MG,14例患有眼肌型MG,3例患有先天性MG。主要观察指标包括眼睑高度和/或位置的改善、术后成功结果的持续时间、是否需要进一步手术干预以及术中或术后并发症。
对23例患者进行了38次上睑下垂手术。手术时的平均年龄为62岁,平均随访29个月。10例患者(16只眼睑)接受了前路提上睑肌缩短术,4例患者(5只眼睑)接受了后路手术,8例患者(15只眼睑)接受了眉悬吊术。1例患者(2只眼睑)进行了睑板移植术。眼睑高度平均改善了1.9毫米。17%的患者出现了术后暴露性角膜病变的症状或体征。这使得1例患者的1只眼睑需要进行眼睑复位。在随访期间,37%的眼睑在平均19个月(范围0.5 - 49个月)后需要进一步手术干预以改善上睑高度。
我们系列中的超过三分之一的患者需要再次手术,当初始目标是对该组患者进行欠矫时,这是可以预期的。与之前的评论相反,眼睑移动量不是指导手术方法的主要因素。